Prof Sherene Loi
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
680 Scholarly works
41 Projects
HIGHLIGHTS
2026
Journal article
Making sense of TILs: recommendations for morphological assessment of tumour-infiltrating lymphocytes in gastro-oesophageal carcinoma : A report on behalf of the International Immuno-Oncology Biomarker Working Group
DOI: 10.1111/his.700892026
Journal article
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial.
DOI: 10.1093/jnci/djag0952026
Research grants (ARC, NHMRC, MRFF)
Innovating in Breast Cancer Immunology Treatment and Prevention
2022
Journal article
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice.
DOI: 10.1038/s43018-022-00413-x2021
Journal article
Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
DOI: 10.1093/jnci/djab1112018
Research Grant
Capture: Circulating Tumour Dna Assessment of Pik3ca to Guide Treatment Response
2018
Research grants (other domestic)
2018 NBCF Endowed Chair Program
RECENT SCHOLARLY WORKS
2026
Journal article
Identifying premenopausal patients with early-stage hormone receptor–positive breast cancer at minimal risk of distant recurrence by breast cancer index
DOI: 10.1016/j.breast.2026.1047142026
Journal article
Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer
DOI: 10.1038/s41571-026-01120-72026
Journal article
DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer
DOI: 10.1158/1078-0432.CCR-25-08742026
Journal article
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02☆
DOI: 10.1016/j.annonc.2025.11.0052026
Journal article
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens
DOI: 10.1001/jamaoncol.2025.53762026
Journal article
Abstract PS5-01-14: Trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd pertuzumab in patients (pts) with previously untreated HER2 unresectable/metastatic breast cancer (mBC): final results from DESTINY-Breast07
DOI: 10.1158/1557-3265.sabcs25-ps5-01-142026
Journal article
Abstract PD7-11: Impact of neoadjuvant pembrolizumab on ovarian function in young patients with triple-negative breast cancer (TNBC): Longitudinal analysis from NeoSTOP and NeoPACT trials
DOI: 10.1158/1557-3265.sabcs25-pd7-112026
Journal article
Abstract PS5-03-09: Trial in progress: A phase 2/3 trial of iza-bren (BMS986507/BL-B01D1), an EGFRxHER3 antibody-drug conjugate, vs standard-of-care chemotherapy in patients with previously untreated, locally advanced, recurrent inoperable, or metastatic triple negative breast cancer ineligible for anti-PD-(L)1 treatment (IZABRIGHT-Breast01)
DOI: 10.1158/1557-3265.sabcs25-ps5-03-09